207
Views
39
CrossRef citations to date
0
Altmetric
Research Article

Mathematical models of cancer dormancy

&
Pages 313-327 | Published online: 01 Jul 2009

REFERENCES

  • Wilbur DL, Hartman HR. Malignant melanoma with delayed metastatic growths. Ann Int Med 1931;5:201–211.
  • Eccles SA, Alexander P. Immunologically-mediated restraint of latent tumour metastases. Nature 1975;257:52–53.
  • Hadfield G. The dormant cancer cell. Br Med J (Clin Res) 1954;2:607–610.
  • Fisher B, Fisher ER. Experimental evidence in support of the dormant tumor cell. Science 1959;130:918–919.
  • Uhr JW, Tucker T, May RD, Siu H, Vitteta ES. Cancer dormancy: studies of the murine BCL1 lymphoma. Cancer Res 1991;51 (Suppl .) :5045s - 5053s.
  • Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nature Med 1997;3:505–509.
  • Slavin S, Strober S. Spontaneous murine B cell leukaemia. Nature 1978;272:624–626.
  • Krolick KA, Isakson PC, Uhr JW, Vitetta ES. BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of the tumor. Immunol Rev 1979;48:81–102.
  • Racila E, Sheuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, Marches R, Street NE, Vitetta ES, Uhr JW. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 1995;181:1539–1550.
  • Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hseuh R, Vitteta ES, Scheuermann RH, Uhr JW. Tumour dormancy and cell signaling-III: role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol 1995;2: 125–136.
  • George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987;138: 628–634.
  • George AJT, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988;141:2168–2174.
  • Morecki S, Pugatsch T, Levi S, Moshel Y, Slavin S. Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1). Int J Cancer 1996;65: 204–208.
  • Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 1994;54:5301–5309.
  • Vitetta ES, Tucker TF, Racila E, Huang Y-W, Marches E, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 1997;89: 4425–4436.
  • Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 1994;56:295–321.
  • Kuznetsov VA, Knott GD. Modeling tumor regrowth and immunotherapy. Math Comp Modelling 2001;33:1275–1287.
  • Adam JA, Belloma N. A survey of models for tumor-immune system dynamics (modeling and simulation in science, engineering and technology). Boston: Birkhaeuser; 1996.
  • Sherratt JA, Nowak MA. Oncogenes, anti-oncogenes and the immune response to cancer: a mathematical model. Proc R Soc Lond B 1992;248:261–271.
  • Owen MR, Sherratt JA. Modelling the macrophage invasion of tumours: effects on growth and composition. IMA J Math Appl Med Biol 1998;15:165–185.
  • Bellomo N, Preziosi L. Modelling and mathematical problems relating to tumor evolution and its interaction with the immune system. Math Comp Modelling 2000;32:413–452.
  • Delsanto PP, Romano A, Scalerandi M, Pescarmona GP. Analysis of a "phase transition" from tumor growth to latency. Phys Rev E 2000;62:2547–2554.
  • Byrne HM. The effect of time delays on the dynamics of avascular tumor growth. Math Biosci 1997;144:83–117.
  • Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1:149–153.
  • O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996;2:689–692.
  • Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangio-genic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404–407.
  • Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response and postvascular dormancy. Cancer Res 1999;59:4770–4775.
  • Roth JA (editor). Monoclonal antibodies in cancer. Advances in diagnosis and treatment. Mount Kisco, New York: Futura Publishing; 1986.
  • Levy R, Miller AR. Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst 1990;10:61–68.
  • Hamblin TJ, Abdul-Ahab AK, Gordon J, Stevenson FK, Stevenson GT. Preliminary experience in treating lympho-cytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. Br J Cancer 1980;42:495–502.
  • Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 1994;54: 1695–1701.
  • Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA, Ullrich A, Slamon D. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Chin Immunol 1991;11: 117–127.
  • Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, Eigler FW, Facklerschwalbe I, Funke I, Schmidt CG, Schreiber H, Schweiberer L, Eibleibesfeldt B. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177 — 1183.
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177 —182.
  • Krikorian JG, Portlock CS, Cooney DP, Rosenberg SA. Spontaneous regression of non-Hodgkins lymphoma: a report of nine cases. Cancer (Phila.) 1980;46:2093–2099.
  • Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23–28.
  • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 2002;3:991–998.
  • McLean AR, Rosado MM, Agenes F, Vasconellos R, Freitas AA. Resource competition as a mechanism for B cell homeostasis. PNAS 1997;94:5792 —5797.
  • Cabatingan MS, Schmidt MR, Sen R, Woodland RT. Naïve B lymphocytes undergo homeostasis proliferation in response to B cell deficit. J Immunol 2002;169:6795–6805.
  • Freitas AA, Rocha B. Population biology of lymphocytes: the flight for survival. Annu Rev Immunol 2000;18:83–111.
  • Agenes F, Rosado MM, Freitas AA. Independent home-ostasis regulation of B cell compartments. Eur J Immunol 1997;27:1801— 1807.
  • Butcher EC, Picker U. Lymphocyte homing and home-ostasis. Science 1996;272:60–66.
  • Orkin SH. Diversification of haematopoiotic stem cells to specific lineages. Nature Rev Gen 2000;1:57–64.
  • Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE. Cancer dormancy. VII. A regulatory role for CD8 + T cells and IFN-y in establishing and maintaining the tumor-dormant state. J Immunol 1999;162: 2842 — 2849.
  • Siu H, Vitetta ES, May RD, Uhr JW. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol 1986;137: 1376–1382.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.